Background/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting. Materials and methods: Data gathered from patients' files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined. Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres- sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve- ment at Month 6 [OR = 0.31, 95% CI (0.14- 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13-0.94), p = 0.037]. Overall, 25 mild adverse events were reported. Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.
23 September 2024 in Turkish Journal of Biochemistry
Objectives: This study aimed to investigate whether patients with primary Sjögren syndrome (SjS) have different levels of 25 OH-D3 (vitamin D) when compared to healthy populations and whether differences in 25 OH-D3 correlated with disease activity or markers. Methods: Eighty-eight female patients with SjS and 3,338 age-matched healthy female controls were included in this study. 25 OH-D3 levels were compared with healthy controls. Then the patients were stratified according to their 25 OH-D3 levels, either insufficient/deficient or normal (<50 nmol/L or ≥50 nmol/L). The disease activity was evaluated using The EULAR SjS disease activity index (ESSDAI) and its components. Correlation analyses were also performed for a possible correlation with disease characteristics and markers of activity. Results: No differences in 25 OH-D3 levels were found between SjS and healthy populations (p>0.05). No correlations were found between patient characteristics or laboratory values (p>0.05). Conclusions: This study did not find a link between disease characteristics and disease activity and 25 OH-D3 levels. Prospective studies with more patients should be conducted to reach a conclusion.
Amaç: Psoriatik Artrit (PsA), sedef hastalığı (PsO) olan hastaların %10-30'unu etkileyen kronik ilerleyici inflamatuar bir hastalıktır. "PsA Sine sedef hastalığı" terimi, "cilt belirtileri olmadan PsA teşhisi konan hastaları" tanımlamak için kullanılır. Bu çalışmada “PsA” “sine psoriasis”in demografik ve klinik özelliklerinin CASPAR kriterlerine göre tanımlanması amaçlandı. Hastalar ve Yöntem: 2016-2022 yılları arasında CASPAR kriterlerine göre PsA sine psoriasis tanısı alan 29 hasta çalışmaya dahil edildi. Romatizmal hastalığı ve herhangi bir cilt tutulumu olan hastalar çalışma dışı bırakıldı. Bulgular: Çalışmaya dahil edilen 29 hastanın tamamına CASPAR kriterlerine göre PsA tanısı konuldu. Hastaların 16'sı kadındı. Hastaların ortalama (±SS) yaşı 45±11 idi. Hastaların ortalama (±SD) PsA süresi 6,2±3,0 yıldı. PsA'lı hastaların birinci derece akrabalarında psoriazis öyküsü %54,1; ikinci derece akrabalarında psöriazis öyküsü ise %45,9 olarak saptandı. Hastaların %39,4'ünde poliartiküler, %35,7'sinde oligoartiküler, %24,9'unda aksiyal tutulum vardı. Tüm hastaların 19'unda (%65,5) DİP tutulumu mevcuttu. Hastaların %88.9'unda tırnak bulguları mevcuttu. Ayrıca hastaların 17'sinde (%58,6) entezit, 18'inde (%62) daktilit saptandı. Sonuç: PsA'yı düşündüren klinik semptom ve bulguları olan ve ailede psöriazis öyküsü olan hastalar, PsA sine psoriasisi olarak sınıflandırılabilir. Daktilit ve DIP artritli hastalar, ailesel sedef hastalığı PsA'nın bir alt grubunu temsil edebilir.